Atrandi Biosciences

High-Level Overview

Atrandi Biosciences is a biotechnology company developing next-generation single-cell analysis technologies, specializing in droplet microfluidics and high-throughput screening workflows for molecular and cellular research.[1][3][4] It builds Semi-Permeable Capsules (SPCs), patented permeable compartments that enable scalable, true single-cell multiomics by isolating tens of thousands of cells for simultaneous bulk processing while preserving single-cell resolution.[3][4] These tools serve academic researchers, biotech firms, and pharmaceutical scientists tackling cellular heterogeneity, clonal evolution, microbiome diversity, and microbial ecology, simplifying complex workflows to accelerate discoveries in life sciences.[1][3][5] With $32 million in total funding, including a $25 million Series A in February 2025, the company—headquartered in Vilnius, Lithuania, with 63 employees—shows strong growth momentum through global commercialization and competition with giants like 10x Genomics and Illumina.[2][3][6]

Origin Story

Founded in 2016 in Vilnius, Lithuania, Atrandi Biosciences (formerly Droplet Genomics) emerged from expertise in droplet microfluidics to address limitations in single-cell analysis.[1][3][5] Key founders include Juozas Nainys, Linas Mažutis, Karolis Leonavičius, Dalius Kučiauskas, and Rapolas Žilionis, who brought backgrounds in biotechnology and microfluidics to create adaptable high-throughput screening tools.[3] Early traction came via a €1 million investment from Practica Capital in 2021 to commercialize droplet technology, followed by funding in 2023 and the pivotal $25 million Series A in 2025 to scale SPC tech globally.[3] The company's name, meaning "you discover" in Lithuanian, reflects its roots in empowering biological research breakthroughs.[3]

Core Differentiators

• Patented SPC Technology: Novel semi-permeable capsules enable true single-cell multiomics in bulk reactions, compartmentalizing tens of thousands of cells for high-resolution analysis of genomic alterations, cellular heterogeneity, and eukaryotic DNA sequencing—outpacing traditional methods.[3][4][6]
• Scalability and Workflow Simplicity: Supports millions of picoliter droplets for high-throughput screening, reducing complexity in multi-step molecular workflows compared to competitors like 10x Genomics and Illumina.[1][5][6]
• Versatility Across Applications: Facilitates research in microbiome diversity, clonal evolution, microbial ecology, and single-cell eukaryotic sequencing, with easily adaptable tools for single-cell and single-molecule resolution.[1][3][5]
• Global Reach from Lithuania: Backed by investors like Practica Capital, it empowers scientists worldwide while leveraging a vibrant local ecosystem.[3]

Role in the Broader Tech Landscape

Atrandi rides the single-cell analysis boom, fueled by demand for precise insights into cellular diversity amid advances in multiomics, genomics, and personalized medicine.[2][4][6] Timing aligns with post-2020 surges in biotech funding for scalable tools, as labs seek alternatives to cumbersome workflows from market leaders.[3][6] Favorable market forces include rising needs in drug discovery, cancer research, and microbiome studies, where SPCs cut costs and boost throughput.[1][3] As a Lithuanian innovator in a Baltic tech hub with supportive ecosystems like Sunrise Tech Park and Unicorns Lithuania, Atrandi influences the startup scene by competing globally, attracting talent, and validating Europe's biotech potential.[1][3]

Quick Take & Future Outlook

Atrandi's $25 million Series A positions it to dominate scalable single-cell multiomics, with SPC commercialization driving adoption in pharma and academia.[2][3] Upcoming trends like AI-integrated omics and expanded eukaryotic sequencing will amplify its edge, potentially capturing share from incumbents amid a projected multi-billion-dollar single-cell market.[2][6] Its influence may evolve through partnerships, new platforms, and ecosystem leadership in Lithuania, turning "you discover" into widespread breakthroughs—building on its tech foundation to redefine biological research.